Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | COMT | P21964 | 4/20 | 0.48 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740965 | 0.90 | FTO (0.62) | KMT2AMEN1COMTFTOMAPT | |
| SCHEMBL32669610 | 0.87 | FTO (0.51) | KMT2AMEN1COMTFTOMAPT | |
| SCHEMBL32669969 | 0.86 | FTO (0.50) | KMT2AMEN1COMTFTOMAPT | |
| SCHEMBL32669579 | 0.85 | FTO (0.49) | KMT2AMEN1COMTFTOMAPT | |
| SCHEMBL32669869 | 0.84 | RAB9A (0.42) | KMT2AMEN1RAB9AESR1 | |
| SCHEMBL32669846 | 0.79 | ALDH1A1 (0.48) | KMT2AMEN1COMTFTOMAPT | |
| SCHEMBL32669815 | 0.79 | FTO (0.50) | KMT2AMEN1COMTFTOMAPT | |
| SCHEMBL32669871 | 0.78 | FTO (0.51) | KMT2AMEN1COMTFTOMAPT | |
| SCHEMBL32670122 | 0.78 | FTO (0.45) | KMT2AMEN1COMTFTO | |
| SCHEMBL32669940 | 0.78 | FTO (0.76) | KMT2AMEN1COMTFTOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | KMT2A 567/4885MEN1 3974/4885COMT 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.